COMMUNIQUÉS West-GlobeNewswire

How Peptide Conjugate Developability Is Shaped Before a Candidate Is Nominated
23/10/2026
Of the 106 peptide and nanobody drug conjugates in active development, roughly 63% are still preclinical, which places many of the decisions that shape manufacturability in the design phase. Cyclization, lipidation, [...]
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
23/10/2026
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Presentation at the [...]
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
23/10/2026
Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was consistent with prior reporting Median relative dose intensity was 84.6%, [...]
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
23/10/2026
AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma [...]
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
23/10/2026
Durable responses observed across multiple tumor types during dose escalation MGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN patients [...]
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
23/10/2026
-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over [...]
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
23/10/2026
Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies [...]
Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer
23/10/2026
Baseline plasma profiling identified three molecular states previously characterized in tissue: androgen receptor (AR)-high/metabolic, stem/epithelial–mesenchymal transition (EMT), and AR-low/proliferative. The AR-high/ [...]
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
23/10/2026
Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone Median rPFS was 9.1 months and rPFS6 was 62.5% in [...]
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
23/10/2026
Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform PRA-216 is a novel IL-4Rα/TSLP bispecific [...]
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
23/10/2026
Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P) , including patients with and without detectable baseline ctDNA. Encouraging disease-free survival outcomes were observed in both ctDNA-negative [...]
Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.
23/10/2026
Opportunity to Connect with Hospital Administrators and Physicians to Foster Expanded Adoption of the LIBERTY System HINGHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and [...]
Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
23/10/2026
Additional $500,000 Advance to Support Growth Initiatives and Working Capital of Realbotix LLC Total Drawn Under Facility Now $3,000,000; Non-Interest Bearing Facility Automatically Cancelled and Discharged in Full Upon [...]
IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026
23/10/2026
ORLANDO, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 third quarter financial results before the market opens on Friday, October 30, [...]
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
23/10/2026
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial [...]
Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)
23/10/2026
Preclinical data demonstrate tumor response with AVA6103 in the setting of Enhertu ® -resistance Potential for prolonged responses with increased FAP+ fibroblasts recruited to the tumor during treatment with AVA6103 [...]
ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following Treatment
23/10/2026
Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting advancement of Padeliporfin VTP for treatment of locally advanced pancreatic cancer 75% (9/12) [...]
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
23/10/2026
- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a [...]
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
23/10/2026
Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery SYDNEY, AUSTRALIA, Oct. 23, 2026 (GLOBE NEWSWIRE) -- [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum